Natera Oct 15, 2021 Natera Builds Data Backing Serial ctDNA Changes to Aid CRC Patient Management, Treatment Decisions Premium Sep 8, 2021 Natera Signatera Test to be Used in Study of MRD-Guided Treatment for Colon Cancer Patients Jul 22, 2021 Natera Minimal Residual Disease Test Predicts Oligometastatic CRC Patient Outcomes in New Study Premium Jul 20, 2021 UK Group Validating Natera ctDNA Test to Guide Therapy for Post-Operative Bladder Cancer Premium Jun 18, 2021 In Brief This Week: Bayer, Saga Diagnostics, Inteliquet, NeoGenomics, Natera May 28, 2021 Guardant Health Sues Natera for False Advertising, 'Misleading' Oncologists About MRD Tests Mar 26, 2021 In Brief This Week: Mirati Therapeutics, Gilead, Natera, Actinium Pharmaceuticals, Myriad Genetics Mar 10, 2021 Genentech Begins Phase III Study of Tecentriq in MRD-Positive Bladder Cancer Feb 26, 2021 Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year Premium Feb 26, 2021 Elicio Therapeutics Sharpens Development Plan for Cancer Vaccine in KRAS-Mutated Tumors Premium Feb 17, 2021 Natera, Personalis Team up for Cancer Treatment Monitoring, MRD Testing Feb 8, 2021 Strata Oncology Launches Large Study Eyeing Competitive Cancer Monitoring, Drug Selection Test Space Premium Jan 20, 2021 Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents Jan 13, 2021 JP Morgan Healthcare, Day 2: Eli Lilly, Pfizer, GlaxoSmithKline, Clovis Oncology, Invitae, and More Dec 4, 2020 Breast Cancer Trial Data Supports Neoadjuvant Use of Natera Liquid Biopsy Premium Oct 2, 2020 Natera Molecular Residual Disease Test to be Used in Breast Cancer Trial of Ibrance Sep 25, 2020 Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD Aug 27, 2020 Natera, MGH to Collaborate in Early-Stage Breast Cancer Clinical Trial of Targeted Therapy Aug 26, 2020 Natera Personalized Liquid Biopsy Cancer Test Receives CE Mark Aug 3, 2020 Natera's Signatera ctDNA Test Shows Immunotherapy Response Prediction Capability in Advanced Cancer Load More Breaking News Enhertu Shows Activity in Early-Stage HER2-Low Breast Cancer Patients in Study Reported at SABCS Dragonfly Therapeutics Begins Phase II Trial of HER2-Targeted NK-Cell Engager Touchlight to Provide DNA Vector for Odimma Therapeutics' Personalized Neoantigen Vaccine Trial FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Caris Life Sciences, Hummingbird Bioscience Partner on Anti-HER3 Therapy Advancement Akeso, Summit Therapeutics Ink $5B Licensing Deal for PD-1/VEGF Bispecific Antibody
